This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
In the United States, ALS is often better known by one of its past victims, the famous baseball player Lou Gehrig. Gehrig was also known as the "Iron Horse" for his unbroken record of 2,130 consecutive ball games. The streak ended in 1939 because of the debilitation caused by ALS. It is therefore particularly ironic that the year his record was broken (1995), by the Baltimore Orioles shortstop Cal Ripken, the first drug for the treatment of ALS, riluzole, was approved by the FDA. The neuropharmacologic basis for the use of riluzole centers on its action as a neuroprotectant against glutamate toxicity. This review will outline the scientific and clinical evidence that suggests that glutamate-mediated toxicity may contribute to motor neuron degeneration in ALS.
There are currently four major hypotheses on the pathogenesis of ALS Table 1 that will be discussed in the articles in this publication: the calcium channel autoantibody hypothesis, the excitotoxic hypothesis, the oxidative stress hypothesis, and the cytoskeletal hypothesis. Other ideas as to the etiology of ALS have also been proposed. [1] In fact, it is very likely that ALS may be caused by a variety of different primary insults, all of which culminate in the final phenotype of upper and lower motor degeneration characteristic of ALS. At least two different pathways already exist; SOD1 gene mutations are present in only 15 to 20% of all familial ALS patients and are not present in the sporadic ALS population [2]; thus, other mutations or risk factors must exist to account for the remaining familial and sporadic patient populations.
- In this window
- In a new window
Table 1. Theories on the etiology of ALS
Neurotransmitter glutamate: normal and abnormal neurotransmission.
Under normal conditions, when the presynaptic terminal is depolarized, glutamate is released in a calcium-dependent process Figure 1. It diffuses across the synaptic cleft where it can activate specific …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
